Management of Neutropenia

Classification and Monitoring

The American College of Physicians recommends calculating the Absolute Neutrophil Count (ANC) by multiplying the total WBC count by the percentage of neutrophils (segmented neutrophils + bands) 1, 2
The American Society of Clinical Oncology classifies neutropenia severity as: Normal (ANC ≥1,500/µL), Mild (ANC 1,000-1,500/µL), Moderate (ANC 500-1,000/µL), Severe (ANC <500/µL), and Profound (ANC <100/µL) 1, 2, 3

The Infectious Diseases Society of America recommends checking for fever (Temperature >38.5°C or 101.3°F for >1 hour) as a medical emergency if ANC <500/µL, requiring immediate evaluation and broad-spectrum antibiotics 4, 5, 1
The American Society of Hematology evaluates for signs of infection (fever, chills, focal signs) and reviews medication history to identify any lymphocyte-depleting therapies or drugs causing neutropenia 1, 4, 5

For ANC ≥1,000/µL, the National Comprehensive Cancer Network recommends no antimicrobial prophylaxis and monitoring CBC weekly for the first 4-6 weeks if on treatments affecting neutrophil counts 1, 3
For ANC 500-1,000/µL, the American College of Clinical Pharmacy recommends holding any causative medications and providing growth factor support (G-CSF) if clinically indicated 4, 5
For ANC <500/µL, the Infectious Diseases Society of America recommends implementing fluoroquinolone prophylaxis and initiating G-CSF therapy, with hematology consultation mandatory 1, 4, 5

The American Society of Clinical Oncology recommends a peripheral blood smear to evaluate cell morphology and rule out atypical lymphocytes or blasts, and viral studies (CMV, EBV, HHV6, parvovirus, HIV, HCV, HBV) 4, 5
The College of American Pathologists recommends flow cytometry if concern for lymphoproliferative disease or paroxysmal nocturnal hemoglobinuria (PNH), and bone marrow biopsy and aspirate if multiple cell lines are abnormal or if aplastic anemia, myelodysplastic syndrome, or leukemia is suspected 4, 5

The American Society of Clinical Oncology recommends weekly CBC for 4-6 weeks for mild neutropenia, and twice weekly CBC during active treatment for moderate to severe neutropenia 1, 3, 4, 5
The National Comprehensive Cancer Network recommends adjusting G-CSF dosing based on neutrophil response, targeting ANC >1,000/µL but <10,000/µL 4, 5